IA Trial Radar
El ensayo clínico NCT07315958 (ALSAC) para Respiratory (Chronic Obstructive Pulmonary Disease) está reclutando. Consulte la vista de tarjeta del Radar de Ensayos Clínicos y las herramientas de descubrimiento de IA para conocer todos los detalles. O haga cualquier pregunta aquí.
Un estudio coincide con los criterios de filtro
Vista de tarjeta
Volver a la búsqueda

Study for Assessing the Prevalence of Airflow Limitation in Outpatients With History of Smoking Attending Cardiology Clinics (ALSAC) 1000 Observacional Diseño adaptativo

Reclutando
Los detalles del ensayo clínico están disponibles principalmente en inglés. ¡Sin embargo, IA Trial Radar puede ayudar! Simplemente haga clic en 'Explicar el estudio' para ver y discutir la información del estudio en el idioma que haya seleccionado.
El ensayo clínico NCT07315958 (ALSAC) es un estudio observacional para Respiratory (Chronic Obstructive Pulmonary Disease). Su estado actual es: reclutando. El estudio se inició el 19 de diciembre de 2025, con el objetivo de reclutar a 1000 participantes. Dirigido por AstraZeneca, se espera que finalice el 30 de septiembre de 2026. Los datos se actualizaron por última vez en ClinicalTrials.gov el 30 de marzo de 2026.
Resumen
Chronic Obstructive Pulmonary Disease (COPD) is a global health concern, associated with structural lung abnormalities causing persistent airflow limitation (AL) and often result from cigarette smoking. In Turkey, COPD was ranked the third among the mortality causes and the eighth among disability causes, with 9.1% to 19.1% prevalence rate. In the Middle East and North Africa (MENA) region, an increase of 30.6% in ag...Mostrar más
Título oficial

A Multinational, Multicenter, Observational, Prospective Cohort Study for Assessing the Prevalence of Airflow Limitation in Outpatients With History of Smoking Attending Cardiology Clinics

Condiciones médicas
Respiratory (Chronic Obstructive Pulmonary Disease)
Otros ID del estudio
  • ALSAC
  • D5980R00124
Número del NCT
NCT07315958
Inicio del estudio (real)
2025-12-19
Última actualización
2026-03-30
Fecha de finalización (estimada)
2026-09-30
Inscripción (prevista)
1000
Tipo de estudio
Observacional
Estado general
Reclutando
Palabras clave
chronic obstructive pulmonary disease
Resultado primario
Medida de resultadoDescripción de la medidaPeriodo de tiempo
Prevalence (number and percentage) of outpatients attending cardiology clinics, with a history of smoking who exhibit concurrent AL consistent with COPD.
Prevalence (number and percentage) of outpatients attending cardiology clinics, with a history of smoking who exhibit concurrent AL consistent with COPD.
1 Year
Resultado secundario
Medida de resultadoDescripción de la medidaPeriodo de tiempo
The proportion of patients with CVD who were previously diagnosed with COPD.
The proportion of patients with CVD who were previously diagnosed with COPD.
1 Year
The distribution of patients with AL consistent with COPD among AL severity GOLD grades 1-4.
The distribution of patients with AL consistent with COPD among AL severity GOLD grades 1-4. GOLD 1 = MILD GOLD 2 = Moderate GOLD 3 = Severe GOLD 4 = Very Severe
1 Year
CAAT score of patients with AL consistent with COPD.
CAAT score of patients with AL consistent with COPD. 10-20: Medium impact on daily life. 20-30: High impact. \>30: Very high impact.
1 Year
The severity of COPD
The severity of COPD using GOLD ABE assessment scheme. Group A: Low Risk, Low Symptoms Group B: Low Risk, High Symptoms Group E: High Risk
1 year
Asistente de participación
Criterios de elegibilidad

Criterios de edad
Niño, Adulto, Adulto mayor
Criterios de sexo
Todos
  1. Patients aged 40 years or older.
  2. Patients with a smoking history of 10 pack-years or more.
  3. Patients willing and able to complete pulmonary function test, using a spirometer.
  4. Patients who have provided written consent to participate in the study.
  5. Patients attending cardiology clinics at the participating centers.
  6. Patients willing and able to complete the CAAT questionnaire.

A. Patients diagnosed with bronchial asthma. B. Patients who used a bronchodilator for an acute respiratory infection before performing spirometry.
AstraZeneca logoAstraZeneca
Contactos centrales del estudio
Contacto: AstraZeneca Clinical Study Information Center, 1-877-240-9479, [email protected]
2 Centros del estudio en 1 países
Research Site, Ankara, Turkey (Türkiye)
Reclutando
Research Site, Istanbul, Turkey (Türkiye)
Reclutando